Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3365510.26442/00403660.2019.05.000232Editorial articleПередовая статьяShort CommunicationComorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapyКоморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапииEliseevM SЕлисеевМаксим Сергеевич

к.м.н., с.н.с. ФГБНУ «НИИР им. В.А. Насоновой»

elicmax@rambler.ruNovikovaA MНовиковаАлександра Михайловна

т. лаборант ФГБНУ «НИИР им. В.А. Насоновой»

V.A. Nasonova Scientific and Research Institute of ReumatologyФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»15052019915VOL 91, NO5 (2019)ТОМ 91, №5 (2019)12012816042020Copyright ©; 2019, Consilium MedicumCopyright ©; 2019, ООО "Консилиум Медикум"2019Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/33655

Nowadays, there is increased interest in the connection of gout and asymptomatic hyperuricemia with comorbid conditions such as diabetes mellitus, cardiovascular diseases, hypertension, chronic kidney disease and other. Studies conducted over the past few decades suggest that not only gout, but also asymptomatic hyperuricemia can significantly worsen the prognosis in patients with cardiovascular diseases, as the deposition of urate crystals can be both an immediate cause and a factor in the progression of renal failure. In that way, the timely appointment of urate - lowering therapy and achieving the target serum uric acid level can not only affect joint damage, but also can significantly slow the progression of life - threatening comorbid conditions.

В настоящее время возрос интерес к связи подагры и асимптоматической гиперурикемии с коморбидными заболеваниями и состояниями, такими как сахарный диабет типа 2, артериальная гипертензия и другие сердечно - сосудистые патологии, хроническая болезнь почек и т.д. Проведенные за последние несколько десятилетий исследования свидетельствуют о том, что не только подагра, но и бессимптомное повышение сывороточного уровня мочевой кислоты может значительно ухудшать прогноз у пациентов с сердечно - сосудистыми заболеваниями, также отложение кристаллов моноурата натрия может быть как непосредственной причиной, так и фактором прогрессирования почечной недостаточности. Таким образом, своевременное назначение уратснижающей терапии и достижение целевого уровня мочевой кислоты способно не только повлиять на поражение суставов, но и может существенно замедлить прогрессирование жизнеугрожающих коморбидных состояний.

gouthyperuricemiauric acidcomorbiditydiabetescardiovascular diseasemetabolic syndromefebuxostatallopurinolподаграгиперурикемиямочевая кислотакоморбидностьсахарный диабетсердечно-сосудистые заболеванияметаболический синдромфебуксостаталлопуринолKuo C.F, Luo S.F. Gout: Risk of premature death in gout unchanged for years. Nat Rev Rheumatol. 2017;13(4):200-1. doi: 10.1038/nrrheum.2017. 27Culleton B.F, Larson M.G, Kannel W.B, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7-13. PMID: 10391820Kuo C.F, Grainge M.J, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case - control study. Ann Rheum Dis. 2016;75(1):210-7. doi: 10.1136/annrh eum dis-2014-206410Choi H.K, Ford E.S, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466Cicero A.F.G, Fogacci F, Giovannini M, et al. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep. 2018;8(1):11529. doi: 10.1038/s41598-018-29955-wShani M, Vinker S, Dinour D, Leiba M, Twig G, Holtzman E.J, Leiba A. High Normal Uric Acid Levels Are Associated with an Increased Risk of Diabetes in Lean, Normoglycemic Healthy Women. J Clin Endocrinol Metab. 2016 Oct;101(10):3772-8. doi: 10.1210/jc.2016-2107Rho Y.H, Lu N, Peloquin C.E, Man A, Zhu Y, Zhang Y, Choi H.K. Independent impact of gout on the risk of diabetes mellitus among women and men: a population - based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(1):91-5. doi: 10.1136/annrheumdis-2014-205827Pan A, Teng G.G, Yuan J.M, Koh W.P. Bidirectional association between diabetes and gout: the Singapore Chinese Health Study. Sci Rep. 2016; 6:25766. doi: 10.1038/srep25766Lytvyn Y, Skrtic M, Yang G.K, Yip P.M, Perkins B.A, Cherney D.Z. Glycosuriamediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308(2):F77-83. doi: 10.1152/ajprenal.00555.2014Елисеев М.С., Барскова В.Г. Нарушения углеводного обмена при подагре: частота выявления и клинические особенности. Терапевтический архив. 2010;82(5):50-4.Agrawal N.K, Kant S. Targeting inflammation in diabetes: newer therapeutic options. World J Diabetes. 2014;5(5):697-710. doi: 10.4239/wjd.v5.i5.697Chen W, Liu X, Ye S. Effects of metformin on blood and urine proinflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;13:34. doi: 10.1186/s12950-016-0142-3Барскова В.Г., Елисеев М.С., Кудаева Ф.М. и др. Влияние метформина на течение подагры и инсулинорезистентность. Клиническая медицина. 2009;87(7):41-6.Matsuura F, Yamashita S, Nakamura T, et al. Effects of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47:929-33. doi: 10.1016/ S0026-0495(98)90346-8Rasheed H, Hughes K, Flynn T.J, Merriman T.R. Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels. Circ Cardiovasc Genet. 2014;7(6):830-7. doi: 10.1161/ CIRCGENETICS.114.000556Johnson R.J, Nakagawa T, Sanchez-Lozada L.G, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307-15. doi: 10.2337/db12-1814Lanaspa M.A, Sánchez-Lozada L.G, Choi Y-J, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose - dependent and -independent fatty liver. J Biol Chem. 2012; 287:40732-44. doi: 10.1074/jbc.M112.399899Cicerchi C, Li N, Kratzer J, et al. Uric acid - dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J. 2014;28:3339-50. doi: 10.1096/fj.13-243634Kuwabara M, Borghi C, Cicero A.F, et al. Elevated Serum Uric Acid Increases Risks for Developing High LDL Cholesterol and Hypertriglyceridemia: A Five-Year Cohort Study in Japan. Int J Cardiol. 2018;261:183-8. doi: 10.5603/CJ.2018.0116Roughley M.J, Belcher J, Mallen C.D, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta - analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. doi: 10.1186/s13075-015-0610-9Yu K.H, Kuo C.F, Luo S.F, et al. Risk of endstage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):R83. doi: 10.1186/ar3806William F. Finn. Kidney Disease and Gout: The Role of the Innate Immune System. Open Urology & Nephrology J. 2016;9(Suppl 1:M3):12. doi: 10.2174/1874303X01609010012Kang D.H, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephol. 2011;31:447-552.Mazzali M, Hughes J, Kim Y.G, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal - independent mechanism. Hypertension. 2001;38:1101-6.Kang D.H, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-97.Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new - onset chronic kidney disease? A systematic review and metaanalysis based on observational cohort studies. BMC Nephrol. 2014;15:122. doi: 10.1186/1471-2369-15-122Jing J, Kielstein J.T, Schultheiss U.T, Sitter T, Titze S.I, Schaeffner E.S, Mc Adams-De Marco M, Kronenberg F, Eckardt K.U, Kottgen A. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant. 2015;30(4):613-21. doi: 10.1093/ndt/gfu352Clarson L.E, Hider S.L, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-7. doi: 10.1136/annrheumdis-2014-205252Clarson L.E, Chandratre P, Hider S.L, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta - analysis. Eur J Prev Cardiol. 2015;22(3):335-43. doi: 10.1177/2047487313514895Choi H.K, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900. doi: 10.1161/ CIRCULATIONAHA.107.703389Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177-82. doi: 10.1136/annrheumdis-2012-202421Елисеев М.С., Денисов И.С., Маркелова Е.И., Глухова С.И., Насонов Е.Л. Независимые факторы риска развития тяжелых сердечно - сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного исследования. Терапевтический архив. 2017; 89(5):10-9. doi:10.17116/terarkh201789510-19Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Medicine. 2017; 15:123. doi: 10.1186/s12916-017-0890-9Richette P, Perez-Ruiz F, Doherty M, Jansen T.L, Nuki G, Pascual E, Punzi L, So A.K, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654-61. doi: 10.1016/j.jare.2017.04.008Perez-Ruiz F, et al. Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout. Arthritis Rheum. ABSTRACT SUPPLEMENT. 2018;70(S9):954-5.Krishnan E, Baker J.F, Furst D.E, Schumacher H.R. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-96. doi: 10.1002/art.22014De Vera M.A, Rahman M.M, Bhole V, Kopec J.A, Choi H.K. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population - based study. Ann Rheum Dis. 2010;69(6):1162-4. doi: 10.1136/ard.2009.122770Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2(1):e000282. doi: 10.1136/bmjopen-2011-000282Harzand A, Tamariz L, Hare J.M. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail. 2012; 18(3):179-82. doi: 10.1111/j.1751-7133.2011.00262.xKuo C.F, Grainge M.J, Mallen C, Zhang W, Doherty M. Impact of gout on the risk of atrial fibrillation. Rheumatology (Oxford). 2016;55(4):721-8. doi: 10.1093/rheumatology/kev418Chang K, Yokose C, Tenner C, et al. Association between gout and aortic stenosis. Am J Med. 2017;130(2):230.e1-8. doi: 10.1016/j.amjmed.2016. 09.005Nakagawa T, Mazzali M, Kang D-H, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23:2-7. doi: 10.115 9/000066303Sánchez-Lozada L.G, Tapia E, Bautista-García P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose - induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294(4):F710-8. doi: 10.1152/ajprenal.00454.2007De Bosch B.J, Kluth O, Fujiwara H, Schurmann A, Moley K. Early - onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642. doi: 10.1038/ncomms5642Kondo M, Imanishi M, Fukushima K, et al. Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-induced Aortic Fibrosis. Am J Hypertens. 2018 Oct 23. doi: 10.1093/ajh/hpy157 [Epub ahead of print.]Namai-Takahashi A, Sakuyama A, Nakamura T, et al. Xanthine oxidase inhibitor, febuxostat ameliorates the high salt intake - induced cardiac hypertrophy and fibrosis in Dahl salt - sensitive rats. Am J Hypertens. 2018 Oct 1. doi: 10.1093/ajh/hpy143Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy - based study. Hypertens Res. 2013;36:43-9. doi: 10.1038/hr.2012.135Saito Y, Nakayama T, Sugimoto K, Fujimoto Y, Kobayashi Y. Relation of lipid content of coronary plaque to level of serum uric acid. Am J Cardiol. 2015;116(9):1346-50. doi: 10.1016/j.amjcard.2015.07.059Ando K, Takahashi H, Watanabe T, Daidoji H, Otaki Y, Nishiyama S, Arimoto T, Shishido T, Miyashita T, Miyamoto T, et al. Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease. J Atheroscler Thromb. 2016;23(8):932-9. doi: 10.5551/jat.33951Park J.J, Roudier M.P, Soman D, Mokadam N.A, Simkin P.A. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014;4(7):e005308. doi: 10.1136/bmjopen-2014-005308Borghi C, Rosei E.A, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-41. Discussion 1741. doi: 10.1097/HJH.0000000000000701Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all - cause mortality: a meta - analysis of prospective studies. Atherosclerosis. 2013;231(1):61-8. doi: 10.1016/j.atherosclerosis.2013.08.023Nozue T, Yamamoto S, Tohyama S, et al. Correlations between serum uric acid and coronary atherosclerosis before and during statin therapy. Coron Artery Dis. 2014;25(4):343-8. doi: 10.1097/MCA.0000000000000084Tamariz L, Hernandez F, Bush A, Palacio A, Hare J.M. Association between serum uric acid and atrial fibrillation: a systematic review and meta - analysis. Heart Rhythm. 2014;11(7):1102-8. doi: 10.1016/j.hrthm. 2014.04.003Kim S.Y, Guevara J.P, Kim K.M, Choi H.K, Heitjan D.F, Albert D.A. Hyperuricemia and risk of stroke: a systematic review and meta - analysis. Arthritis Rheum. 2009;61(7):885-92.Andres M, Quintanilla M.A, Sivera F, et al. Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthritis Rheumatol. 2016;68(6):1531-9. doi: 10.1002/art.39581Grayson P.C, Kim S.Y, La Valley M, Choi H.K. Hyperuricemia and incident hypertension: a systematic review and meta - analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-10. doi: 10.1002/acr.20344Viazzi F, Rebora P, Giussani M, et al. Increased serum uric acid levels blunt the antihypertensive efficacy of lifestyle modifications in children at cardiovascular risk. Hypertension. 2016;67(5):934-40. doi: 10.1161/HYPERTENSIONAHA.115.06852Cicero A.F, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur J Intern Med. 2017;37:38-42. doi: 10.1016/j.ejim.2016.07.026Lv Q, Meng X.F, He F.F, Chen S, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta - analysis of prospective cohort studies. PLoS One. 2013;8(2):e56864. doi: 10.1371/journal.pone. 0056864Yu T.Y, Jee J.H, Bae J.C, et al. Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition. Metabolism. 2016;65(4):432-40. doi: 10.1016/j.metabol.2015.11.003Kleber M.E, Delgado G, Grammer T.B, Silbernagel G, Huang J, Kramer B.K, Ritz E, Marz W. Uric acid and cardiovascular events: a Mendelian randomization study. J Am Soc Nephrol. 2015;26(11):2831-8.Yan D, Wang J, Jiang F, Zhang R, Wang T, Wang S, Peng D, He Z, Chen H, Bao Y, et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: a Mendelian randomization analysis. Int J Cardiol. 2016;214:194-9.Stack A.G, Hanley A, Casserly L.F, Cronin C.J, Abdalla A.A, Kiernan T.J, Murthy B.V, Hegarty A, Hannigan A, Nguyen H.T. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106(7):647-58.Yang Q, Kottgen A, Dehghan A, Smith A.V, Glazer N.L, Chen M.H, Chasman D.I, Aspelund T, Eiriksdottir G, Harris T.B, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3(6):523-30.Pfister R, Barnes D, Luben R, Forouhi N.G, Bochud M, Khaw K.T, Wareham N.J, Langenberg C. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomization approach. Diabetologia. 2011;54(10):2561-9.Hughes K, Flynn T, de Zoysa J, Dalbeth N, Merriman T.R. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int. 2014;85(2):344-51.Sedaghat S, Pazoki R, Uitterlinden A.G, Hofman A, Stricker B.H, Ikram M.A, Franco O.H, Dehghan A. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension. 2014;64(5):1061-6.Sluijs I, Holmes M.V, van der Schouw Y.T, Beulens J.W, Asselbergs F.W, Huerta J.M, Palmer T.M, Arriola L, Balkau B, Barricarte A, et al. A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes. 2015;64(8):3028-36.Keenan T, Zhao W, Rasheed A, Ho W.K, Malik R, Felix J.F, Young R, Shah N, Samuel M, Sheikh N, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67(4):407-16.White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, Shah S, Kruger F.A, Giambartolomei C, Swerdlow D.I, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-36.Higgins P, Dawson J, Lees K.R, Mc Arthur K, Quinn T.J, Walters M.R. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta - analysis. Cardiovasc Ther. 2012;30(4):217-26. doi: 10.1111/j.1755-5922.2011.00277.xNoman A, Ang D.S, Ogston S, Lang C.C, Struthers A.D. Effect of high - dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010; 375(9732):2161-7. doi: 10.1016/S0140-6736(10)60391-1Scheepers L.E, Wei F.F, Stolarz-Skrzypek K, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016;34(11):2147-54. doi: 10.1097/HJH.0000000000001077Scheepers L.E, Boonen A, Pijnenburg W, et al. Associations of plasma uric acid and purine metabolites with blood pressure in children: the KOALA Birth Cohort Study. J Hypertens. 2017;35(5):982-93. doi: 10.1097/HJH.0000000000001270Nomura J, Busso N, Ives A, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014; 4:4554. doi: 10.1038/srep04554Kelley E.E. A new paradigm for XOR-catalyzed reactive species generation in the endothelium. Pharmacol Rep. 2015;67:669-74. doi: 10.1016/j.phar ep.2015.05.004Kushiyama A, Nakatsu Y, Matsunaga Y, et al. Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis. Mediators Inflamm. 2016;2016:8603164. doi: 10.1155/2016/8603164Rekhraj S, Gandy S.J, Szwejkowski B.R, et al. High - dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61:92632. doi: 10.1016/j.jacc.2012.09.066De Abajo F.J, Gil M.J, Rodriguez A, et al. Allopurinol use and risk of non - fatal acute myocardial infarction. Heart. 2015;101:67985. doi: 10.1136/ heartjnl-2014-306670Larsen K.S, Pottegard A, Lindegaard H.M, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016;129:299306 e2. doi: 10.1016/j.amjmed.2015.11.003Thanassoulis G, Brophy J.M, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358-64. doi: 10.11 36/bmjopen-2011-000282Zhang J, Dierckx R, Mohee K, Clark A.L, Cleland J.G. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta - analysis. ESC Heart Fail. 2017 Feb;4(1):40-5.Givertz M.M, Anstrom K.J, Redfield M.M, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the EXACT-HF study. Circulation. 2015;131:1763-71.Agarwal V, Hans N, Messerli F.H. Effect of allopurinol on blood pressure: a systematic review and meta - analysis. J Clin Hypertens. 2013;15:435-42.Qu L.H, Jiang H, Chen J.H. Effect of uric acid - lowering therapy on blood pressure: systematic review and meta - analysis. Ann Med. 2017;49(2):142-56. doi: 10.1080/07853890.2016.1243803Feig D.I, Soletsky B, Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed. essential hypertension: a randomized trial. JAMA. 2008;300:924-32. doi: 10.1001/jama.300.8.924Soletsky B, Feig D.I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60:1148-56. doi: 10.1161/HYPER TENSIONAHA.112.196980Mc Mullan C.J, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin - angiotensin - system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12:807-16. doi: 10.2215/CJN.10771016Kanji T, Gandhi M, Clase C.M, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and metaanalysis. BMC Nephrol. 2015;16:58. doi: 10.1186/s12882-015-0047-zBose B, Badve S.V, Hiremath S.S, et al. Effects of uric acid - lowering therapy on renal outcomes: a systematic review and meta - analysis. Neph Dial Transpl. 2014;29:406-13. doi: 10.1093/ndt/gft378Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long - term follow - up of a randomized clinical trial. Am J Kidney Dis. 2015;65:543-9. doi: 10.1053/j.ajkd.2014.11.016Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid - lowering therapy in patients with chronic kidney disease: A meta - analysis. PLoS One. 2017; 12(11):e0187550. doi: 10.1371/journal.pone.0187550Tanaka K, Nakayama M, Kanno M, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel - group, randomized, controlled trial. Clin Exp Nephrol. 2015;19(6):1044-53. doi: 10.1007/s10157-015-1095-1Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double - blind, randomized, placebo - controlled trial. Am J Kidney Dis. 2015;66:94550. doi: 10.1053/j.ajkd.2015.05.017Baek C.H, Kim H, Yang W.S, Han D.J, Park S.K. Efficacy and Safety of Febuxostat in Kidney Transplant Patients. Exp Clin Transplant. 2018; 16(4):401-6. doi: 10.6002/ect.2016.0367Chou H.W, Chiu H.T, Tsai C.W, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2017 Nov 17. doi: 10.1093/ndt/gfx313Juge P.A, Truchetet M.E, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017;84(5):595-8. doi: 10.1016/ j.jbspin.2016.09.020